Oncothyreon Files New Drug Application for Oncology Drug
Posted on: Friday, 2 May 2008, 06:00 CDT
Oncothyreon has filed an investigational new drug application with the FDA for PX-866, a small molecule phosphatidylinositol-3-kinase inhibitor for the treatment of advanced cancers.
Following FDA review of this investigational new drug application (IND), the company plans to initiate a Phase I clinical trial of PX-866.
Robert Kirkman, president and CEO of Oncothyreon, said: "This IND for PX-866 demonstrates the continued advancement of Oncothyreon's small molecule oncology pipeline. In addition to the planned trial of PX-866, Oncothyreon is currently conducting a Phase II trial of PX-12, a small molecule inhibitor of thioredoxin-1, in patients with advanced pancreatic cancer and a Phase I trial of PX-478, a small molecule inhibitor of HIF-1 alpha, in patients with advanced solid tumors or lymphomas."
Source: Datamonitor
Related Articles
- Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain
- Aegera Initiates Phase 1 Clinical Trial of AEG33773 - A Small Molecule in Development for Diabetic Neuropathic Pain
- Serenex Announces Collaboration With National Cancer Institute to Initiate Clinical Trial With Serenex's Proprietary Small Molecule HSP90 Inhibitor, SNX-5422
- Molecular Design Concepts And Applications Is A Detailed Textbook On The Design Of Small Molecules Is Written With The First Time User In Mind
- 'Hepatitis C - Small-Molecule Antivirals Pave the Way for Triple Therapy' Report Available Now
- Array Begins Dosing for P38 Inhibitor in Phase II Trial
- AngioGenex Files Patent for Small Molecule Id Inhibitors for Cancer
- AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
- Ardea Biosciences' Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
- Sunesis Pharmaceuticals Reports Positive Initial Results From Phase 2 Small Cell Lung Cancer Trial With SNS-595
 |
 |
User Comments (0)
RSS Feeds